Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, collagenase Clostridium histolyticum (Xiapex®) cannot be endorsed for use within NHS Wales for the treatment of adult men with Peyronie's disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy. |
||
|
||
Medicine details |
||
| Medicine name | collagenase Clostridium histolyticum (Xiapex®) | |
| Formulation | 0.9 mg powder and solvent for solution for injection | |
| Reference number | 912 | |
| Indication | Treatment of adult men with Peyronie's disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy |
|
| Company | Swedish Orphan Biovitrum Ltd | |
| BNF chapter | Musculoskeletal & joint diseases | |
| Submission type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 26/06/2015 | |